Metagenomi science chief departs, just a few months after IPO
The chief scientific officer at gene editing company Metagenomi is out, the company confirmed to Endpoints News. “As of yesterday, I have parted ways with Metagenomi by mutual agreement,” CSO Luis...
View ArticleHow SCOTUS' decision in Chevron could change the way the FDA regulates biopharma
The Supreme Court’s decision late last month to overrule a decades-old legal doctrine will have major ramifications for the FDA and the biopharma industry it regulates. Legal scholars warn that the...
View ArticleTwo healthcare SPACs go public, with several more on the hunt for deals
The blank-check acquisition companies Launch One Acquisition and SIM Acquisition went public this week, a signal that the healthcare SPAC trend might not be totally dead. On Friday, Launch One began...
View ArticleClik here to view.
Indivior axes schizophrenia drug and shrinks revenue guidance
Indivior’s shares $INDV have lost nearly a third of their value this week, following the company’s announcement Tuesday that it was shelving a schizophrenia drug and had revised down its 2024 revenue...
View ArticleLilly says lupus drug dropped from pipeline failed to show efficacy
An experimental BTLA agonist that Eli Lilly cut from its pipeline for lupus late last year failed to show strong enough efficacy in a mid-stage trial, the company confirmed to Endpoints News. The...
View ArticleDeep dive on pay packages; Lilly strikes $3.2B buyout; Pfizer’s R&D head to...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
GSK HQ officially returns to central London after decades in city’s suburbs
GSK is moving its global headquarters closer to where it all started. The UK drugmaker is formally shifting Tuesday into a brand new building at the corner of New Oxford Street in central London’s...
View ArticleArtiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline
Clinical-stage cell therapy developer Artiva Biotherapeutics will seek about $116 million in net proceeds from its proposed initial public offering, according to an updated SEC document on Monday...
View ArticleClik here to view.
Updated: Lexeo Therapeutics' gene therapy shows potential for Friedreich's...
Lexeo Therapeutics thinks its gene therapy has the potential for accelerated approval following positive interim data from two early-stage studies, the company announced Monday. Executives say the data...
View ArticleEvofem inks women’s health deal; AusperBio brings in $37M
Plus, news about Enveric, Aries Science, LENZ, MediWound and Destiny Pharma: Evofem acquires antimicrobial: The contraceptive maker is buying Lupin’s US commercial women’s health specialty business for...
View ArticleRevolution Medicines' RAS inhibitor shows promise in early-stage pancreatic...
Revolution Medicines’ experimental drug staved off cancer progression for seven and a half months in second-line metastatic pancreatic cancer patients with a variety of cancer-driving RAS mutations....
View ArticleEMA warns patients to tell doctors about GLP-1 usage before surgery
The European Medicine Agency’s safety committee said that people taking GLP-1s should let their doctor know ahead of surgery in order to avoid respiratory complications. The committee made its...
View ArticleJ&J calls proposed class action talc suit 'meritless' as settlement vote...
Johnson & Johnson asked a federal judge on Thursday to dismiss a proposed class action talc lawsuit, calling it a “misguided effort” to derail ongoing settlement talks. The lawsuit accuses J&J,...
View ArticleClik here to view.
Facing a tepid Alzheimer’s market, Lilly looks to build ‘a sense of urgency’...
On paper, Alzheimer’s disease should be an uncomplicated market for drugmakers. There are millions of potential patients, who until recently had no real option for treatment. And yet the first drugs...
View ArticleClik here to view.
Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2...
Roche shared additional Phase 1b data for the obesity drug it acquired in the Carmot Therapeutics deal that suggest a higher dose had yet to peak at six months. An abstract, which is set to be...
View ArticleClik here to view.
Exclusive: Kins raises $7M to expand in-home and virtual physical therapy
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As purely virtual care models become more popular, physical therapy startup Kins wants to give patients...
View ArticleClik here to view.
CordenPharma injects €900M to boost GLP-1 manufacturing in US and Europe
In its biggest investment so far, CordenPharma is earmarking €900 million ($982 million) over the next three years to expand its peptide platform capacity in the US and Europe to meet rising GLP-1...
View ArticleClik here to view.
Alzheimer's biotech Asceneuron raises $100M to see if it can compete with...
A small Swiss biotech has raised a $100 million Series C to start testing its oral small molecule for Alzheimer’s disease in a Phase 2 later this year. Asceneuron, a Merck KGaA spinout, is developing...
View ArticleVertex takes federal government to court over Casgevy fertility treatment...
Vertex sued the federal government on Monday in an effort to expand its fertility support program to certain patients taking its new gene therapy for sickle cell disease and transfusion-dependent beta...
View ArticleCatalYm raises $150M in Series D to repurpose obesity target for cancer
CatalYm has racked up $150 million in an oversubscribed Series D to advance its antibody drug that neutralizes GDF15 — a target previously explored by other drugmakers for weight loss — through Phase...
View Article